COMP <GO>
COCH vs LLY // DIVIDEND YIELD & FCF PAYOUT SAFETY
Envoy Medical Inc. (Class A) (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: COCH 1
— LLY 8
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: COCH
LAST: $6.63 (+2.00%) • MKT CAP: $50.3M
dividend-safety
3.62%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
dividend-safety
0.49%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COCH VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | COCH | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | -30.00% | 83.64% | -113.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | 40.21% | -100.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 31.90% | -91.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 7.10% | 45.51% | -38.41 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 3.62% | 0.49% | +3.13 | COCH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 9/9 | -7.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.9 | 66.6 | -18.70 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $50.3M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | COCH REV | LLY REV | COCH GROSS % | LLY GROSS % | COCH FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $241.0K | $65.18B | -50.0% | 83.0% | -$18.4M | $16.81B |
| FY 2024 | $225.0K | $45.04B | -50.0% | 81.3% | -$18.9M | $8.82B |
| FY 2023 | $316.0K | $34.12B | — | 79.3% | -$17.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COCH // BETA —
LLY // BETA 0.51